RE: RNS7 Nov 2024 12:35
Developed by Lawrence R. Bernstein, PhD, GaM is a metal-based compound with anticancer activity that can be administered orally. In prior FDA- approved Phase 1 clinical trials, oral GaM demonstrated low toxicity and was well tolerated. Dr. Bernstein is a co-investigator on the trial and will serve as the expert regarding the drug substance and formulations. He will also facilitate sourcing of the clinical-quality GaM. Dr. Chitambar and his colleague, Dr. Jennifer Connelly, MD, Associate Professor of Neurology, will be the co-principal investigators of the trial, which marks the first time an oral form of GaM will be used in GBM patients